A series of cardiometabolic-related news items has been observed from Verdiva Bio, Zealand Pharma, MannKind, FDA, EMA, and Evogene/ELEO. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: D&D Pharmatech extended its oral obesity research agreement with Pfizer (view article), Dexcom received clearance of its G7 15-Day CGM in Canada (view press release), and Insulet partnered with Calm to provide well-being resources for diabetes management (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Rani Therapeutics/PegBio, and Pfizer. Below, FENIX provides highlights and insight for the respective news items.
Following ADA 2026 (June 5-8; New Orleans, LA), FENIX conducted a winners/not winners analysis, identifying the companies that came out on top, remained static, or trended in the wrong direction. As a glimpse into the analysis, Lilly (unsurprisingly) clearly came out on top, with the retatrutide pivotal data session filling the room beyond capacity. The ADA organization seemingly had the most negative outcome following the controversy around Steven Kahn’s removal from the event.
On the second day of the ADA 2026 conference, nine cardiometabolic-related news items have been observed from Pfizer, Abbott, Novo Nordisk, Hengrui/Kailera Therapeutics, Insulet, Dexcom, MannKind, Biomea Fusion, and Tidepool. Below, FENIX provides context and analysis for the announcements.
In the eleventh installment of FENIX’s Obesity Spotlight Series, FENIX has conducted an updated deep dive analysis of Pfizer’s current position in the obesity market. Compared to the previous analysis, which was conducted following the April 2025 termination of danuglipron (previous FENIX insight), this updated Spotlight explores key post‑Metsera acquisition questions, including whether the ~$10B price tag was justified, how Pfizer’s oral AOM strategy is positioned, and whether the company can bring its obesity offering to market sooner than anticipated.
With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.
A series of cardiometabolic-related news items has been observed from Arrowhead, Structure Therapeutics, Senseonics, Tandem Diabetes Care, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed by Pfizer, Madrigal Pharmaceuticals, Novo Nordisk, Vertex Pharmaceuticals, and Cytokinetics. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from CMS, Sanofi, Beta Bionics, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.